Century Therapeutics director granted 74K stock options

Century Therapeutics director Martin Patrick Murphy received a grant of stock options as part of his compensation.

Rhea-AI Filing Summary

Century Therapeutics director Martin Patrick Murphy received a grant of stock options as part of his compensation. He was awarded options covering 74,000 shares of common stock at an exercise price of $2.24 per share, expiring on June 11, 2036.

The option vests on the earlier of June 11, 2027 or the next annual meeting of stockholders, subject to his continued service through the vesting date. Following this grant, he holds options for 74,000 shares directly, with no open-market buying or selling reported in this filing.

Insider Trade Summary

Grant/Award: 74,000 shares

Grant/Award 1 txn

Insider Murphy Martin Patrick

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	74,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 74,000 contracts (Direct)

Footnotes (1)

1. F1. The option vests on the earlier of (a) June 11, 2027, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date.

Key Figures

Options granted: 74,000 options Exercise price: $2.24 per share Underlying shares: 74,000 shares +3 more

6 metrics

Options granted 74,000 options Stock Option (right to buy) grant on June 11, 2026

Exercise price $2.24 per share Conversion or exercise price for the option grant

Underlying shares 74,000 shares Common Stock underlying the granted options

Post-grant derivative holdings 74,000 options Total derivative securities following the reported transaction

Option expiration June 11, 2036 Expiration date of the granted options

Vesting date trigger June 11, 2027 or next annual meeting Earlier date determines vesting, subject to continued service

Key Terms

Stock Option (right to buy), exercise price, vesting, annual meeting of stockholders

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "2.2400""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The option vests on the earlier of (a) June 11, 2027, or (b) the next annual meeting of stockholders"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"the earlier of (a) June 11, 2027, or (b) the next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Century Therapeutics (IPSC) report for Martin Patrick Murphy?

Century Therapeutics reported that director Martin Patrick Murphy received a grant of stock options. The award covers 74,000 shares of common stock, providing the right to buy shares at a fixed exercise price as part of his equity-based compensation package.

How many stock options did Martin Patrick Murphy receive from Century Therapeutics (IPSC)?

Martin Patrick Murphy received options covering 74,000 shares of Century Therapeutics common stock. These options give him the right to purchase up to 74,000 shares, subject to vesting conditions and payment of the stated exercise price when exercised in the future.

What is the exercise price of Martin Patrick Murphy’s Century Therapeutics (IPSC) options?

The options granted to Martin Patrick Murphy have an exercise price of $2.24 per share. This means he can buy Century Therapeutics common stock at $2.24 per share once the options vest and up until they expire, assuming he chooses to exercise them.

When do Martin Patrick Murphy’s Century Therapeutics (IPSC) options vest?

The option vests on the earlier of June 11, 2027 or the next annual meeting of stockholders. Vesting is also conditioned on Murphy’s continued service with Century Therapeutics through the applicable vesting date as specified in the Form 4 footnote.

When do the stock options granted to Martin Patrick Murphy at Century Therapeutics (IPSC) expire?

The granted stock options expire on June 11, 2036. After this expiration date, any unexercised options become void. Until then, once vested, he may choose to exercise them at the fixed exercise price of $2.24 per share.

Did Martin Patrick Murphy buy or sell Century Therapeutics (IPSC) shares on the market in this Form 4?

This Form 4 reports a grant of stock options to Martin Patrick Murphy, not an open-market trade. The transaction is classified as an acquisition through a grant or award, with no reported buying or selling of existing common shares in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 05:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Murphy Martin Patrick

(Last) (First) (Middle)

C/O CENTURY THERAPEUTICS, INC.

25 N 38TH STREET, 11TH FLOOR

(Street)

PHILADELPHIA PENNSYLVANIA 19104

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Century Therapeutics, Inc. [ IPSC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.24	06/11/2026		A		74,000		(1)	06/11/2036	Common Stock	74,000	$0	74,000	D

Explanation of Responses:

1. The option vests on the earlier of (a) June 11, 2027, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ Douglas Carr, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)